Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/06/2791761/0/en/Celcuity-Presents-Preclinical-Data-on-Therapeutic-Effects-of-Gedatolisib-in-Breast-Cancer-Models-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Read more at globenewswire.com

Related news for (CELC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.